REFERENCES 1. Weyer C, Bogardus C, Mott DM, Pratley RE: The nat- ural history of insulin secretory dysfunction and in-sulin resistance in the pathogenesis of type 2 diabetesmellitus. J Clin Invest 1999;104:787–794. 2. U.K. Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: A progressive dis-ease. U.K. Prospective Diabetes Study Group. Dia-betes 1995;44:1249–1258. 3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment andrisk of complications in patients with type 2 diabetes(UKPDS 33). UK Prospective Diabetes Study(UKPDS) Group. Lancet 1998;352:837–853. 4. Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes: Scientific review. JAMA 2002;287:360–372. 5. Mudaliar S, Edelman SV: Insulin therapy in type 2 di- abetes. Endocrinol Metab Clin North Am 2001;30:935–982. 6. Wright A, Burden AC, Paisey RB, Cull CA, Holman